Latest Financials News

Waratah Minerals Limited reported a $2.01 million net cash outflow from operating activities in the December 2024 quarter, ending with $4.23 million in cash and equivalents. The company continues its exploration efforts but faces notable cash burn that may pressure future funding.

Algorae Pharmaceuticals reports robust progress in its drug development pipeline, highlighted by promising preclinical results for cardiovascular and dementia candidates and significant AI platform enhancements.

AUCyber Limited has recommended shareholders accept an increased cash takeover offer from 5G Networks Limited, raising the bid by 22.7% to 13.5 cents per share amid ongoing financial uncertainties.

Actinogen Medical accelerates recruitment in its pivotal XanaMIA Alzheimer's trial while securing a strong cash position of $22.9 million, underpinning its late-stage development and commercial readiness.

Microba Life Sciences reports a remarkable 102% revenue increase in Q2 FY25, driven by strong sales of its MetaXplore test in Australia and promising early traction in the UK. The company also advances its therapeutic pipeline with key clinical milestones.

Agrimin Limited has achieved a major milestone with Western Australian state environmental approval for its Mackay Potash Project, alongside government-backed financial support and strategic progress toward project execution.

Microba Life Sciences reported a robust Q2 FY25 with revenue more than doubling year-on-year, driven by strong sales of its MetaXplore microbiome test in Australia and promising early adoption in the UK.

Babylon Pump & Power Ltd reports robust H1 FY25 results with $1.8M positive operating cash flow and $3.0M EBITDA, overcoming nickel sector challenges. The company eyes growth through new projects and acquisitions.

Whitehaven Coal delivered a robust Q2 FY25 with record sales volumes and production costs at the low end of guidance, while preparing for a major $1.08 billion capital inflow from its Blackwater mine stake sale.

Aroa Biosurgery has reported its first quarter of positive operating cash flow since listing on the ASX in 2020, alongside robust revenue growth projections and new regulatory approvals across key international markets.

Syntara Limited has reported encouraging interim Phase 2 trial results for its lead drug candidate SNT-5505 in myelofibrosis, alongside a successful A$15 million capital raise to advance multiple clinical programs.

Stelar Metals advances exploration at its Baratta Copper Project with new geophysical targets identified in the Bibliando Diapir, reinforcing its potential as a sediment-hosted copper province akin to Africa’s Central Copper Belt.